Cargando…
Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity
Increased uric acid levels have been implicated in the pathogenesis of metabolic syndrome. To examine the mechanisms by which this occurs, we hypothesized that an increase in heme oxygenase 1, a potent antioxidant gene, will decrease uric acid levels and adipocyte dysfunction via suppression of ROS...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670680/ https://www.ncbi.nlm.nih.gov/pubmed/26681956 http://dx.doi.org/10.1155/2016/8197325 |
_version_ | 1782404291032514560 |
---|---|
author | Sodhi, Komal Hilgefort, Jordan Banks, George Gilliam, Chelsea Stevens, Sarah Ansinelli, Hayden A. Getty, Morghan Abraham, Nader G. Shapiro, Joseph I. Khitan, Zeid |
author_facet | Sodhi, Komal Hilgefort, Jordan Banks, George Gilliam, Chelsea Stevens, Sarah Ansinelli, Hayden A. Getty, Morghan Abraham, Nader G. Shapiro, Joseph I. Khitan, Zeid |
author_sort | Sodhi, Komal |
collection | PubMed |
description | Increased uric acid levels have been implicated in the pathogenesis of metabolic syndrome. To examine the mechanisms by which this occurs, we hypothesized that an increase in heme oxygenase 1, a potent antioxidant gene, will decrease uric acid levels and adipocyte dysfunction via suppression of ROS and xanthine oxidase (XO) levels. We examined the effect of uric acid on adipogenesis in human mesenchymal stem cells (MSCs) in the presence and absence of cobalt protoporphyrin (CoPP), an HO-1 inducer, and tin mesoporphyrin (SnMP), an HO activity inhibitor. Uric acid increased adipogenesis by increasing NADPH oxidase expression and elevation in the adipogenesis markers C/EBPα, PPARγ, and Mest, while decreasing small lipid droplets and Wnt10b levels. We treated MSCs with fructose, a fuel source that increases uric acid levels. Our results showed that fructose increased XO expression as compared to the control and concomitant treatment with CoPP significantly decreased XO expression and uric acid levels. These beneficial effects of CoPP were reversed by SnMP, supporting a role for HO activity in mediating these effects. These findings demonstrate that increased levels of HO-1 appear crucial in modulating the phenotype of adipocytes exposed to uric acid and in downregulating XO and NADPH oxidase levels. |
format | Online Article Text |
id | pubmed-4670680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-46706802015-12-17 Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity Sodhi, Komal Hilgefort, Jordan Banks, George Gilliam, Chelsea Stevens, Sarah Ansinelli, Hayden A. Getty, Morghan Abraham, Nader G. Shapiro, Joseph I. Khitan, Zeid Stem Cells Int Research Article Increased uric acid levels have been implicated in the pathogenesis of metabolic syndrome. To examine the mechanisms by which this occurs, we hypothesized that an increase in heme oxygenase 1, a potent antioxidant gene, will decrease uric acid levels and adipocyte dysfunction via suppression of ROS and xanthine oxidase (XO) levels. We examined the effect of uric acid on adipogenesis in human mesenchymal stem cells (MSCs) in the presence and absence of cobalt protoporphyrin (CoPP), an HO-1 inducer, and tin mesoporphyrin (SnMP), an HO activity inhibitor. Uric acid increased adipogenesis by increasing NADPH oxidase expression and elevation in the adipogenesis markers C/EBPα, PPARγ, and Mest, while decreasing small lipid droplets and Wnt10b levels. We treated MSCs with fructose, a fuel source that increases uric acid levels. Our results showed that fructose increased XO expression as compared to the control and concomitant treatment with CoPP significantly decreased XO expression and uric acid levels. These beneficial effects of CoPP were reversed by SnMP, supporting a role for HO activity in mediating these effects. These findings demonstrate that increased levels of HO-1 appear crucial in modulating the phenotype of adipocytes exposed to uric acid and in downregulating XO and NADPH oxidase levels. Hindawi Publishing Corporation 2016 2015-11-22 /pmc/articles/PMC4670680/ /pubmed/26681956 http://dx.doi.org/10.1155/2016/8197325 Text en Copyright © 2016 Komal Sodhi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sodhi, Komal Hilgefort, Jordan Banks, George Gilliam, Chelsea Stevens, Sarah Ansinelli, Hayden A. Getty, Morghan Abraham, Nader G. Shapiro, Joseph I. Khitan, Zeid Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity |
title | Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity |
title_full | Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity |
title_fullStr | Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity |
title_full_unstemmed | Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity |
title_short | Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity |
title_sort | uric acid-induced adipocyte dysfunction is attenuated by ho-1 upregulation: potential role of antioxidant therapy to target obesity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670680/ https://www.ncbi.nlm.nih.gov/pubmed/26681956 http://dx.doi.org/10.1155/2016/8197325 |
work_keys_str_mv | AT sodhikomal uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT hilgefortjordan uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT banksgeorge uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT gilliamchelsea uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT stevenssarah uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT ansinellihaydena uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT gettymorghan uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT abrahamnaderg uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT shapirojosephi uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity AT khitanzeid uricacidinducedadipocytedysfunctionisattenuatedbyho1upregulationpotentialroleofantioxidanttherapytotargetobesity |